VALENCIA, Calif., March 2, 2015 /PRNewswire/ — Valencia Technologies Corporation (“Valencia”) implanted its 48th patient with its radically small device for the treatment of high blood pressure on February 10, 2015. Valencia’s early results in this randomized, double-blinded, controlled trial are compelling and provide the Company with a high degree of confidence that it will succeed in a large U.S. trial for FDA approval.

With its early clinical results, Valencia has successfully raised more than 2.2 million dollars through individual investments starting at $25,000. It will renew the offering on a month-by-month basis to allow individual investment up to final negotiations with institutional investors expected to make up the larger portion of the offering. Such talks are to occur later this year.

Valencia is also entering due diligence with Keiretsu Forum, the largest angel investment group in the world, next week.  Valencia presented to Keiretsu Forum’s four Southern California chapters on February 18th and 19th.

For more information on Valencia’s coin-sized device and its impact on patients, please visit the website at